Your browser doesn't support javascript.
loading
The developments of silicosis drugs / 药学学报
Acta Pharmaceutica Sinica ; (12): 1196-1203, 2023.
Article en Zh | WPRIM | ID: wpr-978704
Biblioteca responsable: WPRO
ABSTRACT
Pneumoconiosis is the most common occupational disease in China, which severely endangers people's health. Depending on the inhaled air pollutants, pneumoconiosis is classified as anthracosis, silicosis, asbestosis, etc., among which silicosis is the most common and serious. Silicosis is a systemic, poor prognostic disease characterized by diffuse fibrosis of lung tissue, which is caused by long-term exposure to dust with high levels of free silicon dioxide (SiO2) in the occupational environment. Appropriate treatment in time is important for the disease. Unfortunately, no effective drugs have been approved to delay or even reverse pulmonary fibrosis caused by SiO2. This review briefly classifies potent therapeutic drugs and compounds in term of mechanisms, providing the probability for clinical treatment of silicosis.
Palabras clave
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Acta Pharmaceutica Sinica Año: 2023 Tipo del documento: Article
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Acta Pharmaceutica Sinica Año: 2023 Tipo del documento: Article